CLINICAL AND EPIDEMIOLOGICAL ASPECTS OF NEUROBRUCELLOSIS ACCORDING TO THE INFORMATION OF SAMARKAND MUNICIPAL INFECTIOUS DISEASES HOSPITAL
Abstract
Brucellosis is a particularly dangerous and socially significant infection that causes considerable economic damage and leads to a high level of patients’ disability (Vershilova P. A., 1961, Beklemishev N. D., 1965). Brucellosis is a global problem for medical and veterinary health services (Corbel M. J., 1997, Boschiroli M. L., 2001). According to the information of WHO Joint Expert Committee on Brucellosis (1986), this disease is registered among animals in 155 countries around the world. Mostly Brucellosis is spread in the Mediterranean countries, Asia Minor, South and South-East Asia, Africa, Central and South America (Sauret I. M. E., 2002; Ergonul O. E. A., 2004; Karabay O. E. A., 2004; Getinkaua Z. E. A., 2005; Alim A., Tomul Z. D., 2005; Onishchenko G. G., 2005) These indices are ten times higher in countries of Central Asia. The registered cases of this disease here are compounded 116 cases per 1 million people in Kazakhstan and 362 in Kyrgyzstan. In Uzbekistan, there are 18 cases per 1 million people. In the Russian Federation there are 4.1 cases per 1 million people, Greece – 21 cases, Germany and the United Kingdom – 0.3 cases.